Logo

Gert Caspritz, Stephane Berghmans

Mar 07, 2008
Premium
EpiCept this week announced that Gert Caspritz has resigned from the company's board of directors, effective March 6.
 
Caspritz, a general partner of TVM Capital, has been a member of the board since 1999 and served as EpiCept's chairman from July 2002 until December 2004.
 
 
Znomics has named Stephane Berghmans as director of drug discovery, effective March 10, the company announced this week.
 
Berghmans was most recently head of safety pharmacology at Summit.

Breaking News
The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.